|
|||||
|
|
| 普萘洛尔治疗婴幼儿血管瘤前后EGFL7的表达变化 | |
| 引用本文： | 刘洁,凌彬,张静,尹小朋,克热木·阿巴斯,扈梅,刘慧,胡露露,龚忠诚,林兆全. 普萘洛尔治疗婴幼儿血管瘤前后EGFL7的表达变化[J]. 中国口腔颌面外科杂志, 2014, 0(5): 416-419 |
| 作者姓名： | 刘洁 凌彬 张静 尹小朋 克热木·阿巴斯 扈梅 刘慧 胡露露 龚忠诚 林兆全 |
| 作者单位： | 新疆医科大学第一附属医院颌面肿瘤外科,新疆医科大学口腔医学院,新疆维吾尔自治区口腔医学研究所.新疆乌鲁木齐830054 |
| 基金项目： | 新疆维吾尔自治区高校科研计划青年教师科研培育基金（XJEDU2012S21） |
| 摘 要： | 目的：研究口服普萘洛尔治疗增殖期婴幼儿血管瘤的临床疗效和治疗过程中表皮生长因子样结构域7（EGFlike domain 7,EGFL7）在血清、尿液中表达的变化。方法：采用ELISA法检测30例患者服药前以及服药后4、12周血清及尿液中EGFL7的水平,分析其与疗效的关系。采用SPSS 17.0软件包对实验数据进行Ridit检验和F检验。结果：2例效果为优（17%）,11例为好（46%）,14例为良（29%）,3例效果差（9%）。治疗前血清EGFL7水平最高（20.62±12.011）μg/mL,服药后4周（13.488±9.826）μg/mL和服药后12周（3.811±2.154）μg/mL,EGFL7水平呈逐渐下降趋势。治疗前尿液EGFL7水平最高（13.373±0.621）μg/mL,服药后4周（9.584±0.659）μg/mL和服药后12周（2.358±0.597）μg/mL,EGFL7水平呈逐渐下降趋势。血清中EGFL7治疗前与治疗后12周比较,有显著差异（P〈0.05）;治疗前与治疗后4周比较,无显著差异（P〉0.05）;治疗后4周与12周比较,无显著差异（P〉0.05）。尿液中EGFL7在治疗前,治疗后4周、12周两两比较,均有显著差异（P〈0.05）。结论：口服普萘洛尔治疗增殖期婴幼儿血管瘤有效,可能是与降低患者血清及尿液EGFL7分子水平有关。 |
| 关 键 词： | 增殖期婴幼儿血管瘤 普萘洛尔 表皮生长因子样结构域7 |
Expression of serum and urine EGF-like domain 7 in proliferative infantile hemangioma treated with oral propranolol |
|
| LIU Jie,LING Bin,ZHANG Jing,YING Xiao-peng,KEREMU Abass,HU Mei,LIU Hui,HU Lulu,GONG Zhong-cheng,LIN Zhao-quan. Expression of serum and urine EGF-like domain 7 in proliferative infantile hemangioma treated with oral propranolol[J]. China Journal of Oral and Maxillofacial Surgery, 2014, 0(5): 416-419 | |
| Authors: | LIU Jie LING Bin ZHANG Jing YING Xiao-peng KEREMU Abass HU Mei LIU Hui HU Lulu GONG Zhong-cheng LIN Zhao-quan |
| Affiliation: | . (Department of Maxillofacial Surgical Oncology, the First Teaching Hospital of Xinjiang Medical University, College of Stomatalogy, Xinjiang Medical University, Research Institute of Stomatology, Xinjiang Uygur Autonomous Region. Urumqi 830054, Xinjiang Uygar Autonomous Region, China) |
| Abstract: | PURPOSE： To investigate the effect of oral propranolol in treating proliferating infantile haemangiomas, and the changes of EGF-like domain 7（EGFL7） during treatment. METHODS： ELISA was used to measure the serum and urine concentrations of EGFL7 in normal people and children with proliferating infantile hemangiomas before, 4 and 12 weeks after oral propranolol treatment. The data was analyzed using SPSS 17.0 software package for Ridit test and F test.RESULTS： The response was excellent in 2 patients, good in 11, moderate in 14, and poor in 3 patients. The serum EGFL7（20.62±12.011 μg/mL） was high before treatment, then decreased 4 weeks（13.488±9.826 μg/mL） and 12 weeks（3.811±2.154 μg/mL） after treatment. The urine EGFL7（13.373±0.621 μg/mL） was high before treatment, then decreased4 weeks（9.584±0.659 μg/mL） and 12 weeks（2.358±0.597 μg/mL） after treatment. The serum EGFL7 was significantly lower 12 weeks after treatment（P〈0.05）. There was no significant difference between pre-treatment and 4 weeks after treatment（P〉0.05）, between 4 and 12 weeks after treatment（P〉0.05）. The urine EGFL7 was significantly lower 4 or 12 weeks after treatment（P〈0.05）. CONCLUSIONS： Propranolol can be safely and effectively used to treat proliferating infantile hemangiomas. It can reduce the peripheral serum and urine concentrations of EGFL7 in affected children.（2013211A080）. |
| Keywords: | Proliferating infantile hemangioma Propranolol EGFL7 |
| 本文献已被 维普 等数据库收录！ | |